Onat, A. And Direskeneli, H. 2012. Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy. CURRENT PHARMACEUTICAL DESIGN , vol.18, no.11 , 1465-1477.

Onat, A., & Direskeneli, H., (2012). Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy. CURRENT PHARMACEUTICAL DESIGN , vol.18, no.11, 1465-1477.

Onat, Altan, And Haner Direskeneli. "Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy," CURRENT PHARMACEUTICAL DESIGN , vol.18, no.11, 1465-1477, 2012

Onat, Altan And Direskeneli, Haner. "Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy." CURRENT PHARMACEUTICAL DESIGN , vol.18, no.11, pp.1465-1477, 2012

Onat, A. And Direskeneli, H. (2012) . "Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy." CURRENT PHARMACEUTICAL DESIGN , vol.18, no.11, pp.1465-1477.

@article{article, author={Altan Onat And author={Haner Direskeneli}, title={Excess Cardiovascular Risk in Inflammatory Rheumatic Diseases: Pathophysiology and Targeted Therapy}, journal={CURRENT PHARMACEUTICAL DESIGN}, year=2012, pages={1465-1477} }